Legend Biotech

We are a global #celltherapy company focused on developing, manufacturing and commercializing #cancer treatments. $LEGN

[Legend Biotech @LegendBiotech]

#LegendNews at #EHA2026. We’ll present initial Phase 1 LB2501 data in relapsed/refractory B-cell NHL in a late-breaking oral presentation. The abstract highlights encouraging clinical activity and a favorable safety profile.

Learn more: https://t.co/1lTEqrcu00

@EHA_Hematology

[Legend Biotech @LegendBiotech]

Following the LB2102 announcement, CEO Ying Huang shares his perspective on the importance of continued research in solid tumors.

[Legend Biotech @LegendBiotech]

#LegendNews: At #ASCO26, we shared new data highlighting the potential of CAR-T cell therapy, including encouraging early Phase 1 results for investigational LB2102 in solid tumors.

Read more: https://t.co/cDsKV7LEAP

#Oncology #CellTherapy

[Legend Biotech @LegendBiotech]

One theme emerging across conversations this week is how quickly oncology research continues to evolve and where next-generation innovation could help shape the future of treatment.

[Legend Biotech @LegendBiotech]

The best part of #ASCO26 continues to be the exchange of ideas, perspectives, and experiences happening across the community. More conversations ahead tomorrow.

[Legend Biotech @LegendBiotech]

Quick pulse check from the floor at #ASCO26: We asked attendees what conversations are shaping the future of oncology right now. A lot of answers started with the same idea: momentum.

[Legend Biotech @LegendBiotech]

Another question we asked attendees: “What gives you hope in oncology innovation right now?” #ASCO26

[Legend Biotech @LegendBiotech]

More conversations ahead from Chicago. #ASCO26 #CellTherapy

[Legend Biotech @LegendBiotech]

The energy at #ASCO26 feels different this year. More conversations around earlier intervention. More momentum behind cell therapy. More urgency around what comes next. A few reflections from the Legend team onsite today.

[Legend Biotech @LegendBiotech]

We asked a few of our leaders what they’re most excited about heading into the weekend. Their response wasn’t a single study or session. Instead, it highlighted the momentum across the oncology community. #ASCO26

[Legend Biotech @LegendBiotech]

We’re at the @ASCO Annual Meeting this week. 👋

Attending? Swing by booth #21955 to learn more about how we’re advancing cell therapy in multiple myeloma and beyond. Also, check out our Heroes in Practice display honoring community oncologists.

#ASCO26 #CART #CellTherapy

[Legend Biotech @LegendBiotech]

On #WorldBloodCancerDay, we recognize the patients, care partners, and communities impacted by #BloodCancers.

We remain committed to advancing innovation and supporting efforts to improve outcomes for patients.

#PatientsFirst

[Legend Biotech @LegendBiotech]

At #ASCO26, we’re bringing together members of the oncology community for an evening of conversation around the future of cell therapy, innovation, and what’s next in oncology.

📅 May 30
🕕 6:30-9:30 PM CT

For more information, contact your local MSL. https://t.co/RI1Q43Mo1F

[Legend Biotech @LegendBiotech]

#ASCO26 starts this week. We’ll be sharing new data across our CAR-T portfolio, including investigational findings in solid tumors and new analyses in multiple myeloma.

Stop by booth #21955 if you’re attending.

#CellTherapy

[Legend Biotech @LegendBiotech]

Our #ASCO26 Investor Relations event is happening on Sunday, May 31. Join us as we discuss CAR-T therapies and our progress in multiple myeloma.

Register here: https://t.co/IfmenPeUud

#CellTherapy

[Legend Biotech @LegendBiotech]

#LegendNews: Early LB2102 data in solid tumors will be presented at #ASCO26.

Additional data presented at @ASCO reinforce established efficacy and safety profile in #MultipleMyeloma.

Come find us at ASCO Booth #21955 to learn more and read more at: https://t.co/BZuAPKZwIF